Liraglutide Selectively Reduces Belly Fat While Preserving Lean Mass in Just 18 Days
Short-term liraglutide (18 days) selectively reduced android and trunk fat while preserving lean and bone mass, with decreased C-peptide and modestly increased IGF-1 in patients with type 2 diabetes.
Quick Facts
What This Study Found
Liraglutide over 18 days reduced total mass (p=0.04), android fat % (p=0.04), and trunk fat (p=0.04) with no lean/bone changes. C-peptide decreased (p=0.026), IGF-1 modestly increased (p=0.002). No MAFI axis changes.
Key Numbers
How They Did This
Randomized double-blind placebo-controlled crossover trial in 20 adults with T2D, 18-day liraglutide (up to 1.8 mg/day) vs placebo with washout, DXA regional body composition, and MAFI hormone panel.
Why This Research Matters
Knowing that fat loss starts quickly and targets the most dangerous fat (abdominal) while sparing muscle provides early reassurance for patients starting GLP-1 therapy.
The Bigger Picture
The selective android fat loss within 18 days suggests GLP-1 drugs preferentially mobilize the metabolically dangerous visceral fat depot first.
What This Study Doesn't Tell Us
Very short (18 days). Small sample (n=20). May not predict longer-term composition changes. Crossover design may have carryover effects despite washout.
Questions This Raises
- ?Does the selective android fat loss persist with longer treatment?
- ?Is the IGF-1 increase a compensatory mechanism protecting lean mass?
- ?Would these body composition changes differ at higher GLP-1 doses?
Trust & Context
- Key Stat:
- Belly fat first Just 18 days of liraglutide selectively reduced the most dangerous fat (android/trunk) while leaving muscle and bone untouched
- Evidence Grade:
- Small but well-designed randomized crossover RCT with DXA body composition. Limited by short duration and sample size.
- Study Age:
- Published in 2025.
- Original Title:
- Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.
- Published In:
- Diabetes, obesity & metabolism, 28(2), 1258-1265 (2026)
- Authors:
- Gutierrez de Piñeres, Valeria(2), Tamayo-Torres, Claudia S(2), Ramirez-Cisneros, Arantxa(2), Kavelidou, Marianthi, Stefanakis, Konstantinos, Mantzoros, Christos S
- Database ID:
- RPEP-15244
Evidence Hierarchy
Frequently Asked Questions
Does liraglutide burn belly fat specifically?
Yes. Within just 18 days, this study found liraglutide selectively reduced android (belly) and trunk fat while leaving muscle and bone mass completely unchanged.
Will I lose muscle on GLP-1 drugs?
Not in the short term. This careful 18-day study with DXA scanning showed no lean mass or bone changes. The body appears to selectively burn fat stores first.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15244APA
Gutierrez de Piñeres, Valeria; Tamayo-Torres, Claudia S; Ramirez-Cisneros, Arantxa; Kavelidou, Marianthi; Stefanakis, Konstantinos; Mantzoros, Christos S. (2026). Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.. Diabetes, obesity & metabolism, 28(2), 1258-1265. https://doi.org/10.1111/dom.70313
MLA
Gutierrez de Piñeres, Valeria, et al. "Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover study.." Diabetes, 2026. https://doi.org/10.1111/dom.70313
RethinkPeptides
RethinkPeptides Research Database. "Effects of liraglutide treatment for 18 days on metabolic pa..." RPEP-15244. Retrieved from https://rethinkpeptides.com/research/gutierrez-2026-effects-of-liraglutide-treatment
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.